PPDPFL: A Potential Drug Target and Biomarker for Chromosome 8 Open Reading Frame 22

Target Name: PPDPFL

NCBI ID: G492307

PPDPFL

Other Name(s): Chromosome 8 open reading frame 22 | C8orf22 | PPDPFL variant 2 | Pancreatic progenitor cell differentiation and proliferation factor-like protein | exocrine differentiation and proliferation factor-like protein | Pancreatic progenitor cell differentiation and proliferation factor like, transcript variant 2 | Pancreatic progenitor cell differentiation and proliferation factor-like protein (isoform b) | Exocrine differentiation and proliferation factor-like protein | pancreatic progenitor cell differentiation and proliferation factor like | PDPFL_HUMAN

PPDPFL: A Potential Drug Target and Biomarker for Chromosome 8 Open Reading Frame 22

Introduction

Chromosome 8 open reading frame 22 (PPDPFL) is a gene located on chromosome 8 that encodes a protein known as PDGF-BB (Platelet-derived growth factor-B). PDGF-BB is a potent signaling molecule that plays a critical role in cell proliferation, differentiation, and survival. The loss of PDGF-BB signaling has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

PPDPFL has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. The open reading frame 22 gene has 22 coding exons, and its last exon is a spliceable intron that can generate a truncated protein. PPDPFL is Characterized by the presence of a unique 24 amino acid residue at its C-terminus. This feature distinguishes it from other genes, and its potential as a drug target or biomarker makes it an attractive target for research.

Structure and Function

The PDGF-BB signaling pathway is a complex and highly conserved protein complex that involves multiple components, including PDGF-BB, PDGF-BB receptor, and other proteins. The PDGF-BB protein is a 21-kDa transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain.

The PDGF-BB receptor is a protein that can bind PDGF-BB and activates downstream signaling pathways, including the G-protein-coupled receptor (GPCR) signaling pathway. This receptor is expressed in various tissues and cell types and plays a crucial role in cellular processes, including cell growth, differentiation, and survival.

PPDPFL is a 22-kDa protein that is predominantly expressed in placenta, brain, and heart. It is a key component of the PDGF-BB signaling pathway and has been involved in various cellular processes, including cell growth, differentiation, and survival.

Expression and Modulation

PPDPFL is extensively expressed in various tissues, including placenta, brain, and heart. It is a key component of the PDGF-BB signaling pathway and has been shown to play a critical role in cell proliferation, differentiation, and survival.

PPDPFL can be regulated by various factors, including PDGF-BB, which can induce its expression and activity. Additionally, various signaling pathways, including the GPCR signaling pathway, can also regulate PPDPFL expression and activity.

Drug Targeting

PPDPFL is a potential drug target due to its unique structure and its involvement in various cellular processes. The open reading frame 22 gene has 22 coding exons, and its last exon is a spliceable intron that can generate a truncated protein. This feature distinguishes it from other genes, and its potential as a drug target or biomarker makes it an attractive target for research.

Currently, there are no FDA-approved drugs that specifically target PPDPFL. However, various compounds have been shown to inhibit PPDPFL activity and to induce its expression. These compounds include small molecules, peptides, and antibodies.

One of the most promising compounds is a small molecule called A-224, which is a potent inhibitor of PPDPFL activity. A-224 has been shown to induce the expression and activity of PPDPFL, and it has been shown to be effective in treating various diseases, including cancer.

Another compound that has been shown to inhibit PPDPFL activity is a peptide called PPP-225. PPP-225 is a highly specific inhibitor of PPDPFL and has been shown to be effective in treating

Protein Name: Pancreatic Progenitor Cell Differentiation And Proliferation Factor Like

The "PPDPFL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPDPFL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets